Summary We have established a subline (EMT6/VRP) of the mouse tumour cell line EMT6/P with acquired resistance to the calcium transport blocker verapamil (VRP). The subline was 4-fold resistant to the cytoxicity of VRP alone compared with the parent line but of similar sensitivity to adriamycin, vincristine or colchicine. EMT6/VRP cells growing in 75 jig ml-' VRP were morphologically different from and larger in diameter than EMT6/P cells, but these two parameters reverted almost to normal within 3 days of VRP removal, although resistance was retained. Expression of an mRNA coding for P-glycoprotein was similar in EMT6/VRP and the parent cell line, although considerable hyperexpression was seen in a multidrug resistant subline, EMT6/ ARI.0. Cellular accumulation of both 3H-daunorubicin and 3H-VRP were greater in EMT6/VRP than in the parent line. Sensitisation to adriamycin by 3.3 jig ml-' VRP was, however, somewhat reduced in EMT6/VRP (i.e. to 6.1-fold) compared with the 11-fold sensitisation seen in the parent line. It is clear that resistance to VRP seen in this cell line occurs via a different mechanism from the resistance to drugs such as adriamycin, vincristine and colchicine seen in multidrug resistant cell lines.
One approach to the problem of multidrug resistance (MDR) in cancer chemotherapy is the use of agents ('resistance modifiers') which partially restore drug sensitivity to resistant cells. The resistance modifier which has been most widely studied is the calcium transport blocker verapamil (VRP) (Tsuruo et al., 1981 (Tsuruo et al., , 1983 Slater et al., 1982; Twentyman et al., 1986a; Coley et al., 1989a,b) . In most studies it has been found that VRP produces greater sensitisation to drugs involved in MDR (e.g. adriamycin (ADM), vincristine, colchicine) in MDR cells than in their sensitive counterparts. The action of VRP appears to be related to the potent drug efflux mechanism which prevails in MDR cells, probably mediated by P-glycoprotein (Tsuruo et al., 1982; Fojo et al., 1985; Bradley et al., 1988) . Recent data have indicated that VRP is capable of binding to P-glycoprotein and may thus competitively inhibit the binding of the cytotoxic drugs to the molecule (Cornwell et al., 1987) .
One interesting observation has been that MDR cells are sometimes more sensitive to VRP alone than their sensitive counterparts (Twentyman et al., 1986a; Warr et al., 1986 Warr et al., , 1988 Cano-Gauci & Riordan, 1987) although this is not always so. Furthermore, Cano-Gauci and Riordan (1987) (Twentyman et al., 1986b; Coley et al., 1989a,b) (Mosmann, 1983) . The assay has been modified by us and its use with EMT6 cells has been previously described (Twentyman & Luscombe, 1987 (Taylor, 1980) was added to I ml of cell suspension. The cells were then run through the Cambridge flow cytometer (Watson, 1980) using an argon laser operating at 488 nm. DNA content per nucleus was measured on the basis of the fluorescence output from each nucleus. Size distributions were determined on cell suspension diluted in 'Isoton' (Coulter) and analysed using a Coulter ZBI particle counter.
Isotope uptakes Tritium-labelled VRP hydrochloride (3H-VRP) (60 Ci mmol-') and tritium-labelled daunorubicin (an ADM analogue) (3H-DNR) (4.2 Ci mmol-') were obtained from New England Nuclear. Labelled DNR was used in these experiments in common with many previous studies, because of its greater availability compared to labelled ADM. Cells were inoculated into wells on six-well multiplates (3 cm diameter, Sterilin Ltd) 48 h before experiments. Initial numbers of cells per well were adjusted so that equal numbers of cells per well would be present at the time of the experiments, and these were 4 x 104 per well for EMT6/P; 5 x 104 per well for EMT6/ARI.0 and 6 x 104 per well for EMT6/VRP. The latter two cell types were grown in the absence of drug over this 48 h period. To commence experiments, the medium was aspirated from each well and replaced with 2 ml of medium at 37°C containing the labelled compound (0.1IlCi ml-') plus unlabelled compound to give a final concentration of 0.5 igml-' or 0.4 tgmlm' for VRP or DNR respectively.
After the appropriate incubation time, the medium was again aspirated from each well and the cells were rinsed three times with ice cold PBS. One ml of distilled water was then added to each well and the wells were left for 2 h for cell lysis to occur. At the end of this time, the contents of each well were pipetted several times and 0.5 ml transferred to a glass scintillation vial containing 10 ml of Aquasol (New England Nuclear Twenty ltg of total cellular RNA in 1O mM sodium phosphate buffer (pH 7.0) was denatured in 1.0 M glyoxal for 1 h at 50°C (Thomas, 1980) . The RNA was then fractionated by electrophoresis in a 1.4% agarose gel in 10 mM sodium phosphate buffer and was transferred by Northern blotting to nylon filters (Thomas, 1980) . After treatment for 2 min with ultraviolet light, the nylon filters were baked at 80°C for 2 h before hybridisation.
The pcDRl.3 proble for the mouse A DRIl gene coding for P-glycoprotein (Gros et al., 1986) Feinberg and Vogelstein (1984) .
The labelled probe, at a concentration of 106 counts min-' ml-' was hybridised to the filter in I M NaCl, 0.1 M trisodium citrate (6 x SSC), 5% dextran sulphate, 0.02% Ficoll, 0.02% bovine serum albumen, 0.02% polyvinyl pyrrolidone (Denhardt, 1966) previously been shown to be proportional to final cell number.
In three experiments, the RF was determined in parallel for the EMT6/VRP line maintained in VRP and for the cells after a period of growth in the absence of the selecting drug.
The results are shown in Table I (Figure 3 ). This change occurred gradually as the dose of VRP was increased. The EMT6/ VRP cells (Figure 3b ) have a much rounder shape, a more granular appearance and a more distinct nucleus than EMT6/P (Figure 3a) . After 3 days growth in the absence of VRP, however, the appearance of EMT6/VRP cells had almost reverted to normal (Figure 3c ). Whereas the doubling time of the EMT6/VRP cells maintained in VRP was considerably greater than that of the parent line (17 vs 12 h) the doubling time returned to 12 h immediately following removal of VRP. EMT6/VRP cells growing in the presence of the VRP were significantly larger in volume than cells of the parent line (Figure 4) . After 3 days growth in the absence of VRP, however, the size of the EMT6/VRP cells had reverted to normal. The DNA distributions obtained by flow cytometry of EMT6/VRP cells growing both in the presence or absence of VRP were unchanged from the distribution given by EMT6/P cells (data not shown). expression in the EMT6/VRP line was similar to that seen in the EMT6/P parent line. This is in contrast to the considerable hyperexpression seen in EMT6IARI.O.
Accumulation of co-VRP and H-DNR 3
The results of experiments to determine the accumulation of labelled VRP and labelled DNR by EMT6/P, EMT6/ARI .0 and EMT6/VRP cells are shown in Figure 6 and Table II The data are shown in Table III . The EMT6/P line is unusual in that more sensitisation to ADM by 3.3 lag ml-' VRP is seen in the parent line than in the MDR line EMT6/ ARlO. (Coley et al., 1989a Although the EMT6/VRP cells are relatively resistant to VRP, they also accumulate more 3H-VRP than the parent cells. This is in striking contrast to data for 3H-VRP accumulation in MDR cell lines which are VRP hypersensitive (Cano-Gauci & Riordan, 1987; Warr et al., 1988) . In these two studies, 3H-VRP accumulation was < 10% and 20% of parent line levels in cells with VRP-hypersensitivity. Additionally in our EMT6/ARI.0 cell line, which is 50-fold resistant to ADM compared with the EMT6/P parent, there is a modest resistance to VRP cytotoxicity at the same time as a small reduction in 3H-VRP accumulation (Reeve et al., 1989) . These results taken together apparently indicate that VRP sensitivity is inversely proportional to VRP accumulation. While it is difficult to propose a mechanistic basis for such an inverse relationship, it is clear that cellular accumulation is not the main determinant of VRP sensitivity. This is in contrast to the situation for MDR cell lines where resistance is almost invariably associated with reduced accumulation of MDR type drugs (Bradley et al., 1988) .
Resistance to VRP alone is accompanied by a small reduction in the ability of cells to be sensitised to ADM by VRP (from I 1.0-fold to 6. 1-fold). In previous studies (unpublished) of the sensitisation of EMT6/P cells to ADM at different VRP doses, we have found that a sensitisation ratio of 8.3 at 3.3 pg ml-' of VRP was reduced to 5.5 at 1.65 fig ml' of VRP. It is clear therefore that a 4-fold reduction in sensitivity to VRP alone is accompanied by a similar reduction in VRP sensitisation to ADM produced by a 2-fold reduction in VRP dose. The biochemical targets for the two processes may therefore be overlapping but more detailed dose-response data will be needed to ascertain whether or not they are identical. Furthermore, as the VRP resistant cells accumulate more VRP than the parent line, it is clear that intercellular VRP concentration is not the determining factor for ADM sensitisation and possibly therefore that an internal domain of P-glycoprotein is not the relevant site for such sensitisation.
The above analysis assumes that the accumulation of 3H-VRP reflects the intracellular concentration of the agent. This is by analogy to the intracellular accumulation of agents such as 3H-DNR. If, however, 3H-VRP is being irreversibly accumulated on the outside of the cell membrane, then analysis of the data becomes more complicated and a variety of alternative approaches become possible.
We will in the future examine in more detail the location of bound 3H-VRP in the three cell types described in this paper. This will include measurement of 3H-VRP binding to isolated plasma membranes and to TCA-precipitated high molecular weight material. Such studies should allow further elucidation of the relationship between VRP sensitivity, VRP sensitisation to MDR type drugs and the biochemical determinants of the MDR phenotype.
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